A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma
Daniel Lee(Ulsan College), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Jamie Leigh Brewer(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Michael H. Brave(United States Food and Drug Administration), Jaleh Fallah(United States Food and Drug Administration), Haley Gittleman(University of California San Diego), Harpreet Singh(United States Food and Drug Administration), Daniel L. Suzman(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Sundeep Agrawal(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Chana Weinstock(United States Food and Drug Administration), Erik Bloomquist(Center for Drug Evaluation and Research)
Cited by 19
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k